Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31626083 | 0.81 | CYP4F2 (0.49) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL10004678 | 0.81 | CYP4F2 (0.48) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL186963 | 0.80 | CYP4F2 (0.51) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL18044818 | 0.79 | CYP4F2 (0.43) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL186673 | 0.78 | CYP4F2 (0.53) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL798227 | 0.78 | CYP4F2 (0.60) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL797984 | 0.78 | CYP4F2 (0.60) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL798441 | 0.78 | CYP4F2 (0.60) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL14903599 | 0.78 | CYP4F2 (0.46) | CYP4F2CYP4A11DGAT1TDP1 | |
| SCHEMBL798199 | 0.78 | CYP4F2 (0.60) | CYP4F2CYP4A11DGAT1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856110-B1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7737163-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7705020-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-7595329-B2 | Benzimidazolone carboxylic acid derivatives | PFIZER INC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7589109-B2 | Oxyindole derivatives | PFIZER INC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER INC | 2005-12-15 | — | — | US | disclosed |
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | PFIZER JAPAN INC. (JP) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277673-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | CYP4F2 1097/4885CYP4A11 615/4885DGAT1 4189/4885 |
| US-20050277672-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | CYP4F2 1097/4885CYP4A11 615/4885DGAT1 4189/4885 |
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | CYP4F2 715/4885CYP4A11 422/4885DGAT1 2695/4885 |
| US-20050277671-A1 | Benzimidazolone carboxylic acid derivatives | HRH2, HRH4, GPR4 | CYP4F2 1097/4885CYP4A11 615/4885DGAT1 4189/4885 |
| US-20080108660-A1 | Benzimidazolone Carboxylic Acid Derivatives | HRH2, HRH4, GPR4 | CYP4F2 1184/4885CYP4A11 672/4885DGAT1 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.